Lipo Hydroxy Acid
DrugTwice a day
Other names: Effaclar AI, 2-hydroxy 5-octanoyl benzoic acid, LHA, C8-LHA, capryloyl salicylic acid
NCT Number: NCT00624676
Acne vulgaris is a frequent inflammatory skin condition involving the pilosebaceous unit and affecting more than 80% of teenagers. Mild to moderate acne vulgaris is usually treated with topical agents such as benzoyl peroxide, retinoids and antibiotics. These treatments can be associated with local tolerance problems and/or antibiotic resistance. Salicylic acid has been shown to be an effective treatment for acne. LHA is a lipophilic hydroxy acid derivative of salicylic acid that has comedolytic and antibacterial properties.
The objective of this trial was to compare the efficacy and tolerance of a cream formulation containing 0.3% LHA (LHA formulation) to a 5% benzoyl peroxide gel.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Innovaderm Research, Laval, Quebec, Canada
This was a randomized clinical trial performed at two centers (Montreal and Laval, Quebec, Canada) under the direction of the same principal investigator. Eighty (80) subjects were enrolled in the study. Subjects were asked to report to the clinic for four visits (D0, D28, D56, D87). The LHA formulation was applied twice a day (morning and evening) and benzoyl peroxide was applied daily (evening) on a clean face for a total of 12 weeks.
Efficacy was evaluated at day 28, 56 and 87. The number of papules, pustules, opened and closed comedones were counted at each visit by a blinded assessor. The overall efficacy was evaluated with a 4-point scale (no improvement, moderate, good and excellent) by the subject and the blinded assessor. Clinical examination included evaluation of sensitivity of the skin (presence of erythema and desquamation) by the investigator and of pruritus, tingling and burning sensation by subjects on a 4-point scale. Finally, the subject and the skin assessor both evaluated overall tolerance on a 4-point scale.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Twice a day
Other names: Effaclar AI, 2-hydroxy 5-octanoyl benzoic acid, LHA, C8-LHA, capryloyl salicylic acid
Once a day
Other names: PanOxyl 5
Time frame: Days 28, 56 and 87
Time frame: Days 28, 56 and 87
Time frame: Days 28, 56 and 87
Time frame: Days 28, 56 and 87
Time frame: Days 28, 56 and 87
Time frame: Days 28, 56 and 87
Cosmetique Active International
Industry
Randomized Study Comparing the Efficacy and Tolerance of a Lipophilic Hydroxy Acid Derivative of Salicylic Acid and 5% Benzoyl Peroxide in the Treatment of Facial Acne Vulgaris
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05080764
Acne Vulgaris, Acneiform Eruptions
Fountain Valley, California, United States
View Trial DetailsNCT07652112
Acne Vulgaris, Acneiform Eruptions
Kayseri, Turkey (Türkiye)
View Trial DetailsNCT06415279
Acne Vulgaris, Acneiform Eruptions
High Point, North Carolina, United States
View Trial DetailsNCT07244887
Acne Vulgaris, Acneiform Eruptions
Istanbul, Turkey (Türkiye)
View Trial Details